GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.

Item
http://www.wikidata.org/entity/Q34041838
Novel bile acid therapeutics for the treatment of chronic liver diseasesTreatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directionsEarly investigational drugs targeting PPAR-α for the treatment of metabolic disease.Pharmacotherapy for Nonalcoholic Fatty Liver Disease.PPARs: regulators of metabolism and as therapeutic targets in cardiovascular disease. Part II: PPAR-β/δ and PPAR-γ.Innate Immunity and Inflammation in NAFLD/NASH.Treatment of nonalcoholic fatty liver disease: Where do we stand? an overview.Development and validation of a noninvasive prediction model for nonalcoholic steatohepatitis resolution after lifestyle intervention.NAFLD and diabetes mellitus.PPAR-α agonists are still on the rise: an update on clinical and experimental findings.The selective peroxisome proliferator-activated receptor-delta agonist seladelpar reverses nonalcoholic steatohepatitis pathology by abrogating lipotoxicity in diabetic obese mice.
P2860

GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.

Item
http://www.wikidata.org/entity/Q34041838
description
2014 nî lūn-bûn
@nan
2014 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2014 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2014年の論文
@ja
2014年論文
@yue
2014年論文
@zh-hant
2014年論文
@zh-hk
2014年論文
@zh-mo
2014年論文
@zh-tw
2014年论文
@wuu
name
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@ast
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@en
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@nl
type
label
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@ast
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@en
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@nl
prefLabel
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@ast
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@en
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@nl
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
GFT505 for the treatment of nonalcoholic steatohepatitis and type 2 diabetes.
@en
P2093
P2860
P304
P31
P356
10.1517/13543784.2014.954034
P407
P433
P478
P50
P577
P698
P921